|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver transplantation for hepatocellular carcinoma:Role of inflammatory and immunological state on recurrence and prognosis显示文摘Criteria for liver transplantation(LT)for hepatocellular carcinoma(HCC)and post-LT indicators of prognosis are historically based on the measurement of the tumor mass.Recently,high throughput technologies have increased the prediction of recurrence,but these tools are not yet routinely available.The interaction between HCC and the immune system has revealed an imbalance of lymphocyte phenotypes in the peritumoral tissue,and the increase of regulatory T cells with respect to cytotoxic lymphocytes has been linked to a higher rate of post-LT HCC recurrence.Moreover,some inflammatory markers have shown good reliability in predicting cancer reappearance after surgery,as a result of either a systemic inflammatory response or a decreased capacity of the organism to control the tumor growth.Among these markers,the neutrophil-tolymphocyte ratio appears to be the most promising and easily available serum parameter able to predict HCC recurrence after LT and following other types of treatment,although the exact mechanisms determining its elevation have not been clarified.Post-LT immunosuppression may impact on cancer control,and the exposure to high levels of calcineurin inhibitors or other immunusuppressants has recently emerged as a negative prognostic factor for HCC recurrence and patient survival.Despite the absence of prospective randomized trials,inhibitors of the mammalian target of rapamycin have been shown to be associated with lower rates of tumor recurrence compared to other immunosuppressors,suggesting their use especially in patients with HCC exceeding the conventional indication criteria for LT. | Matteo Cescon Valentina Rosa Bertuzzo Giorgio Ercolani Matteo Ravaioli Federica Odaldi Antonio Daniele Pinna | 2013 | World Journal of Gastroenterology2013，19，48： | 8 |
| 2 | Non-invasive tests for the prediction of primary hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC)is one of the most common malignancies in the world and it is one of the main complications of cirrhosis and portal hypertension.Even in the presence of a well-established follow-up protocol for cirrhotic patients,to date poor data are available on predictive markers for primary HCC occurrence in the setting of compensated advanced chronic liver disease patients(cACLD).The gold standard method to evaluate the prognosis of patients with cACLD,beyond liver fibrosis assessed with histology,is the measurement of the hepatic venous pressure gradient(HVPG).An HVPG≥10 mmHg has been related to an increased risk of HCC in cACLD patients.However,these methods are burdened by additional costs and risks for patients and are mostly available only in referral centers.In the last decade increasing research has focused on the evaluation of several,simple,non-invasive tests(NITs)as predictors of HCC development.We reviewed the currently available literature on biochemical and ultrasound-based scores developed for the noninvasive evaluation of liver fibrosis and portal hypertension in predicting primary HCC.We found that the most reliable methods to assess HCC risk were the liver stiffness measurement,the aspartate aminotransferase to platelet ratio index score and the fibrosis-4 index.Other promising NITs need further investigations and validation for different liver disease aetiologies. | Giovanni Marasco Antonio Colecchia Giovanni Silva Benedetta Rossini Leonardo Henry Eusebi Federico Ravaioli Elton Dajti Luigina Vanessa Alemanni Luigi Colecchia Matteo Renzulli Rita Golfieri Davide Festi | 2020 | World Journal of Gastroenterology2020，26，24： | 8 |
| 3 | Liver transplantation for hepatic tumors:a systematic review显示文摘Improvements in the medical and pharmacological management of liver transplantation(LT)recipients have led to a better long-term outcome and extension of the indications for this procedure.Liver tumors are relevant to LT;however,the use of LT to treat malignancies remains a debated issue because the high risk of recurrence.In this review we considered LT for hepatocellular carcinoma(HCC),cholangiocarcinoma(CCA),liver metastases(LM)and other rare tumors.We reviewed the literature,focusing on the past 10 years.The highly selected Milan criteria of LT for HCC(single nodule<5 cm or up to 3 nodules<3cm)have been recently extended by a group from the University of S.Francisco(1 lesion<6.5 cm or up to3 lesions<4.5 cm)with satisfying results in terms of recurrence-free survival and the'up-to-seven criteria'.Moreover,using these criteria,other transplant groups have recently developed downstaging protocols,including surgical or loco-regional treatments of HCC,which have increased the post-operative survival of recipients.CCA may be treated by LT in patients who cannot undergo liver resection because of underlying liver disease or for anatomical technical challenges.A well-defined protocol of chemoirradiation and staging laparotomy before LT has been developed by the Mayo Clinic,which has resulted in long term diseasefree survival comparable to other indications.LT for LM has also been investigated by multicenter studies.It offers a real benefit for metastases from neuroendocrine tumors that are well differentiated and when a major extrahepatic resection is not required.If LT is an option in these selected cases,liver metastases from colorectal cancer is still a borderline indication because data concerning the disease-free survival are still lacking.Hepatoblastoma and hemangioendothelioma represent rare primary tumors for which LT is often the only possible and effective cure because of the frequent multifocal,intrahepatic nature of the disease.LT is a very promising procedure for both primary and secondary liver malignancies;however,it needs an accurate evaluation of the costs and benefits for each indication to balance the chances of cure with actual organ availability. | Matteo Ravaioli Giorgio Ercolani Flavia Neri Matteo Cescon Giacomo Stacchini Massimo Del Gaudio Alessandro Cucchetti Antonio Daniele Pinna | 2014 | World Journal of Gastroenterology2014，20，18： | 8 |
| 4 | Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: Is it necessary?显示文摘AIM: To assess the safety and effectiveness of prophylaxis for venous thromboembolism (VTE) in a large population of patients with hepatocellular carcinoma (HCC) on cirrhosis.METHODS: Two hundred and twenty nine consecutive cirrhotic patients with HCC who underwent hepatic resection were retrospectively evaluated to assess whether there was any difference in the incidence of thrombotic or hemorrhagic complications between those who received and those who did not receive prophylaxis with low-molecular weight heparin.Differences and possible effects of the following parameters were investigated: age,sex,Child-Pugh and model for end-stage liver disease (MELD) score,platelet count,presence of esophageal varices,type of hepatic resection,duration of surgery,intraoperative transfusion of blood and fresh frozen plasma (FFP),body mass index,diabetes and previous cardiovascular disease.RESULTS: One hundred and fifty seven of 229 (68.5%) patients received antithromboembolic prophylaxis (group A) while the remaining 72 (31.5%) patients did not (group B).Patients in group B had higher Child-Pugh and MELD scores,lower platelet counts,a higher prevalence of esophageal varices and higher requirements for intraoperative transfusion of FFP.The incidence of VTE and postoperative hemorrhage was 0.63% and 3.18% in group A and 1.38% and 1.38% in group B,respectively;these differences were not significant.None of the variables analyzed including prophylaxis proved to be risk factors for VTE,and only the presence of esophageal varices was associated with an increased risk of bleeding.CONCLUSION: Prophylaxis is safe in cirrhotic patients without esophageal varices;the real need for prophylaxis should be better assessed. | Marco Vivarelli Matteo Zanello Chiara Zanfi Alessandro Cucchetti Matteo Ravaioli Massimo Del Gaudio Matteo Cescon Augusto Lauro Eva Montanari Gian Luca Grazi Antonio Daniele Pinna | 2010 | World Journal of Gastroenterology2010，16，17： | 6 |
| 5 | Is Portal Hypertension a Contraindication to Hepatic Resection?显示文摘 | Alessandro Cucchetti Giorgio Ercolani Marco Vivarelli Matteo Cescon Matteo Ravaioli Giovanni Ramacciato Gian Luca Grazi Antonio Daniele Pinna | 2009 | Annals of Surgery2009，，6： | 5 |
| 6 | ZnO材料的电子输运特性显示文摘用全带 Monte Carlo方法模拟了纤锌矿 Zn O材料电子的稳态和瞬态输运特性 .稳态输运特性包括稳态平均漂移速度 -电场特性、电子平均能量 -电场特性和在不同电场下电子按能量的分布 .在平均漂移速度 -电场特性中发现了微分负阻效应 .Zn O的瞬态输运特性包括平均漂移速度 -位移关系曲线、渡越时间 -位移关系曲线等 .在平均漂移速度 -位移关系曲线中发现了过冲现象 ,这种现象是电子从低能谷到高能谷跃迁过程中的弛豫时间产生的 . | 郭宝增 王永青 宗晓萍 孙荣霞 宋登元 Umberto Ravaioli Maritin Staedele | 2003 | Journal of Semiconductors2003，24，7： | 3 |
| 7 | Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients显示文摘AIM To investigate changes in spleen stiffness measurements(SSMs) and other non-invasive tests(NITs) after treatment with direct-acting antivirals(DAAs) and identify predictors of SSM change after sustainedvirological response(SVR). METHODS We retrospectively analysed 146 advanced-chronic liver disease(ACLD) patients treated with DAA with available paired SSM at baseline and SVR24. Liver stiffness(LSM), spleen diameter(SD), platelet count(PLT) and liver stiffness-spleen diameter to platelet ratio score(LSPS) were also investigated. LSM ≥ 21 k Pa was used as a cut-off to rule-in clinically significant portal hypertension(CSPH). SSM reduction > 20% from baseline was defined as significant.RESULTS SSM significantly decreased at SVR24, in both patients with and without CSPH; in 44.8% of cases, SSM reduction was > 20%. LSPS significantly improved in the entire cohort at SVR24; SD and PLT changed significantly only in patients without CSPH. LSM significantly decreased in 65.7% of patients and also in 2/3 patients in whom SSM did not decrease. The independent predictor of decreased SSM was median relative change of LSM. CSPH persisted in 54.4% patients after SVR. Delta LSM and baseline SSM were independent factors associated with CSPH persistence.CONCLUSION SSM and other NITs significantly decrease after SVR, although differently according to the patient's clinical condition. SSM faithfully reflects changes in portal hypertension and could represent a useful NIT for the follow-up of these patients. | Federico Ravaioli Antonio Colecchia Elton Dajti Giovanni Marasco Luigina Vanessa Alemanni Mariarosa Tamè Francesco Azzaroli Stefano Brillanti Giuseppe Mazzella Davide Festi | 2018 | World Journal of Hepatology2018，10，10： | 3 |
| 8 | Liver Resection for Hepatocellular Carcinoma on Cirrhosis: Univariate and Multivariate Analysis of Risk Factors for Intrahepatic Recurrence显示文摘 | Giorgio Ercolani Gian Luca Grazi Matteo Ravaioli Massimo Del Gaudio Andrea Gardini Matteo Cescon Giovanni Varotti Francesco Cetta Antonino Cavallari | 2003 | Annals of Surgery2003，，4： | 2 |
| 9 | Liver Transplantation for Hepatocellular Carcinoma Under Calcineurin Inhibitors: Reassessment of Risk Factors for Tumor Recurrence显示文摘 | Marco Vivarelli Alessandro Cucchetti Giuliano La Barba Matteo Ravaioli Massimo Del Gaudio Augusto Lauro Gian Luca Grazi Antonio Daniele Pinna | 2008 | Annals of Surgery2008，，5： | 2 |
| 10 | Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation显示文摘 | Fabio Piscaglia Alice Gianstefani Matteo Ravaioli Rita Golfieri Alberta Cappelli Emanuela Giampalma Elisabetta Sagrini Grazia Imbriaco Antonio Daniele Pinna Luigi Bolondi | 2010 | Liver Transpl2010，，： | 2 |
| 11 | Hepatocellular Carcinomas and Primary Liver Tumors as Predictive Factors for Postoperative Mortality after Liver Resection: A Meta-Analysis of More than 35,000 Hepatic Resections显示文摘 | Ramacciato Giovanni D’Angelo Francesco Baldini Rossella Petrucciani Niccoló Antolino Laura Aurello Paolo Nigri Giuseppe Bellagamba Riccardo Pezzoli Francesca Balesh Albert Cucchetti Alessandro Cescon Matteo Del Gaudio Massimo Ravaioli Matteo | 2012 | EN2012，，4： | 2 |
| 12 | Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice显示文摘Patients with cirrhosis show an increased susceptibility to infection due to disease-related immune-dysfunction.Bacterial infection therefore represents a common,often detrimental event in patients with advanced liver disease,since it can worsen portal hypertension and impair the function of hepatic and extrahepatic organs.Among pharmacological strategies to prevent infection,antibiotic prophylaxis remains the first-choice,especially in high-risk groups,such as patients with acute variceal bleeding,low ascitic fluid proteins,and prior episodes of spontaneous bacterial peritonitis.Nevertheless,antibiotic prophylaxis has to deal with the changing bacterial epidemiology in cirrhosis,with increased rates of gram-positive bacteria and multidrug resistant rods,warnings about quinolonesrelated side effects,and low prescription adherence.Short-term antibiotic prophylaxis is applied in many other settings during hospitalization,such as before interventional or surgical procedures,but often without knowledge of local bacterial epidemiology and without strict adherence to antimicrobial stewardship.This paper offers a detailed overview on the application of antibiotic prophylaxis in cirrhosis,according to the current evidence. | Alberto Ferrarese Nicola Passigato Caterina Cusumano Stefano Gemini Angelo Tonon Elton Dajti Giovanni Marasco Federico Ravaioli Antonio Colecchia | 2021 | World Journal of Hepatology2021，13，8： | 2 |
| 13 | Comparison of Recurrence of Hepatocellular Carcinoma After Resection in Patients with Cirrhosis to Its Occurrence in a Surveilled Cirrhotic Population显示文摘 | Alessandro Cucchetti MD Fabio Piscaglia MD Eugenio Caturelli MD Luisa Benvegnù MD Marco Vivarelli MD Giorgio Ercolani MD Matteo Cescon MD Matteo Ravaioli MD Gian Luca Grazi MD Luigi Bolondi MD Antonio Daniele Pinna MD | 2009 | Annals of Surgical Oncology2009，，2： | 2 |
| 14 | Differential negative resistance effect of output characteristics in deep sub-micrometer wurtzite AlGaN/GaN MODFETs显示文摘We obtained the output characteristics in wurtzite Al0.15Ga0.85N/GaN MODFETs with the full band Monte Carlo method. The gate length L g and the channel length LDS in the device are 0.2 μm and 0.4 μm, respectively. In the output characteristics we found a differential negative resistance effect. That is, as VGS is a constant, initially, I DS increases with increasing V DS. When V DS exceeds a certain critical value, I DS decreases with increasing VDS. The analysis for velocity-field characteristics in wurtzite GaN, the distributions of the electric field and the electron velocity in the two dimensional electron gas channel indicates that the differential negative resistance effect of the electron average velocity results in the differential negative resistance effect of the output characteristics. The transient transport also is related to the differential negative resistance effect of the output characteristics. This effect only can be observed in the devices with very short channel. | 郭宝增 Umberto Ravaioli | 2003 | Science in China(Series F)2003，46，3： | 2 |
| 15 | Properties of wurtzite GaN MESFETs studied by two-dimensional full band Monte Carlo approach显示文摘 | Guo B Ravaioli U Song D | 2004 | Microelectronics Journal2004，35，2： | 1 |
| 16 | Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience显示文摘 | Gaudio M D Ercolani G Ravaioli M | 2008 | Am J Transplant2008，8，6： | 1 |
| 17 | Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation 显示文摘 | Fiorentino M Altimari A Ravaioli M | 2004 | Clin Cancer Res2004，10，： | 1 |
| 18 | Liver resection for hepato- cellular carcinoma on cirrhosis:univariate and multivariate analysis of risk factors for intrahepatic recurrence显示文摘 | Ercolani G Grazi G L Ravaioli M | 2003 | Ann Surg2003，237，4： | 1 |
| 19 | The role of lymphadenectomy for liver tumors: further considerations on the appropriateness of treatment strategy显示文摘 | Ereolani ( Grazi GL Ravaioli M el al | 2004 | Ann Surg2004，239，2： | 1 |
| 20 | A revised consid- eration on the use of very aged donors for liver transplan- tation显示文摘 | Grazi GL Cescon M Ravaioli M | 2001 | Am J Transplant2001，1，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员